Connect with us

Health

Novartis to Invest $100m to Research, Develop New Antimalarials

Published

on

By Modupe Gbadeyanka

The management of Novartis has announced a five-year commitment to the fight against malaria in conjunction with the 7th Multilateral Initiative on Malaria Conference and the Malaria Summit of the Commonwealth Heads of Government meeting.

Further, the company has released new African research on progress and remaining challenges toward the 2030 malaria elimination targets, together with Elimination 8 and the KEMRI-Wellcome Trust program.

Over the next five years, as part of its commitment, Novartis will invest more than $100 million to advance research and development of next-generation treatments to combat emerging resistance to artemisinin and other currently used antimalarials.

The company will also implement an equitable pricing strategy to maximize patient access in malaria-endemic countries when these new treatments become available.

In order to contribute to the WHO’s target of reducing malaria-related child mortality by at least 90 percent by 2030, Novartis will further help expand access to pediatric antimalarials and implement healthcare system strengthening programs in 4 sub-Saharan countries.

“Resistance to treatment presents the biggest threat to the incredible progress that has been made in the fight against malaria in the past 20 years. We cannot afford to wait; this is why we are committing to advance the research and development of next-generation treatments,” said Vas Narasimhan, CEO of Novartis. “At the same time, we need to work to ensure that our innovation reaches those most in need, even those in the most remote locations.”

The R&D investment is meant to advance the Novartis malaria pipeline through 2023 and to complete a comprehensive global clinical trial program for our novel antimalarial drug candidates KAF156 and KAE609 (currently in Phase IIb and Phase IIa respectively). Both are from new classes of medicines that were selected for their ability to treat malaria in different ways from current therapies. The investment also includes new uses of technology to identify areas where the malaria burden is greatest. This information could then be used to support capability- and capacity-building to establish future clinical trial sites, so the medicines can be evaluated in the populations where they are most needed.

In order to enable patients in malaria-endemic countries to afford these new treatments once they become available, the company will implement an equitable pricing strategy based on socio-economic conditions of different population segments. We plan to do so in consultation with our development and funding partners and other stakeholders.

Despite the tremendous progress made in combating malaria, one child still dies from the disease every two minutes. Novartis aims to contribute to the WHO’s target of reducing malaria-related child mortality by at least 90 percent in 2030. In Nigeria, the Democratic Republic of Congo and at least two more countries in sub-Saharan Africa that bear the highest number of malaria-related child deaths, we plan to work with partners to help expand access to our paediatric artemisinin-based combination therapy (ACT) and drive integrated community case management (iCCM) initiatives.

iCCM is recognized as a key strategy for increasing access to essential treatments and reducing child mortality from treatable conditions, such as malaria, pneumonia and diarrhoea.

Novartis has been committed to the fight against malaria for the past two decades, launching the first fixed-dose ACT in 1999 and the first dispersible paediatric ACT developed in partnership with Medicines for Malaria Venture (MMV) in 2009.

To date, working with partners, the company has delivered more than 850 million treatments, including 350 million paediatric treatments, without profit to malaria-endemic countries.

The new commitment launches at the same time as results from a new research study (Malaria Futures for Africa, MalaFA) across 14 countries in sub-Saharan Africa.

In total, 68 African experts from governments, the research community and nongovernmental organizations expressed their views on progress and remaining challenges toward the 2030 global malaria elimination targets.

Global malaria deaths have fallen by more than 60 percent between 2000 and 2015. Yet respondents fear progress could stall unless national governments provide more funding and international organizations target their support more effectively.

Many experts also voiced concerns that mosquitoes were increasingly resistant to insecticides and that malaria parasites could become resistant to ACTs in the next 15-20 years. Some feared that resistance would spread faster because of expanding trade and travel between Africa and Asia, where the first signs of drug resistance are emerging. Others thought it was just as likely that resistance could emerge independently in Africa.

Respondents expressed widespread support for making better use of the currently available tools, while stressing that more emphasis should be placed on improving the delivery of existing and new interventions to fight malaria – an area currently underfunded.

The MalaFA study was commissioned by Novartis and co-chaired by Dr Richard Kamwi, Ambassador, Elimination 8 (E8), and Professor Bob Snow, of the KEMRI-Wellcome Trust program, Kenya and University of Oxford, United Kingdom. Research advisers include Roll Back Malaria, Malaria No More UK and the African Leaders Malaria Alliance.

According to the 2017 World Malaria Report, there were 216 million cases of malaria in 2016, up from 211 million cases in 2015. The number of malaria deaths was 445,000 in 2016 vs. 438,000 in 2015. Ninety percent of malaria cases and over 90 percent of malaria deaths occur in sub-Saharan Africa. Children under 5 are particularly at risk, and malaria takes the life of a child every two minutes.

Modupe Gbadeyanka is a fast-rising journalist with Business Post Nigeria. Her passion for journalism is amazing. She is willing to learn more with a view to becoming one of the best pen-pushers in Nigeria. Her role models are the duo of CNN's Richard Quest and Christiane Amanpour.

Click to comment

Leave a Reply

Health

Sault Tribe Enacts Smoking Ban in Kewaunee

Published

on

Ban smoking Sault Tribe

Health and comfort have become increasingly essential issues lately, and this has not gone unnoticed in entertainment venues. The Sault Tribe, which operates the Kewadin Casino, has decided to ban smoking in five gambling establishments. This innovation is aimed at creating a healthier environment for all visitors and employees.

Health and comfort come first

Tribal representatives emphasized that people’s health is their top priority. The decision to ban smoking was a logical step toward positive change. “As a tribal government, we are focused on improving health, and the move to ban smoking in casinos is the right step forward,” notes one tribal speaker. This means caring about the health of visitors and the well-being of the employees who work in these facilities daily.

The Sault Tribe has been actively gathering opinions from its customers and employees, and the results have been unequivocal: many are in favor of banning smoking. “We have heard from many customers and employees that a smoking ban is the right step forward,” states a tribal spokesperson. Such feedback confirms that concern for health and well-being is becoming increasingly important to the gambling industry.

What will change at Kewadin casinos?

In the weeks following the passage of the amendments, Kewadin casinos located in Sault Ste. Marie, St. Ignace, Manistique, Christmas, and Hessel will begin implementing the new policy. The smoking ban will be in effect in all establishments, including gaming rooms, restaurants, and recreational facilities. This approach will not only make the casino experience more enjoyable for non-smoking visitors, but it will also create a safer environment for employees who spend much time in the gaming rooms.

Positive implications for business and society

The adopted initiative will not only bring health benefits but will also affect the success of businesses in the long run:

  • The actions taken also emphasize the Sault Tribe’s social responsibility. They are not just in business but also show concern for the well-being of their customers and employees, making them an example for other gambling establishments.
  • Banning smoking in Kewadin casinos will create a more pleasant environment for both non-smokers and those looking to quit smoking. Smoking in public places often makes other visitors uncomfortable, and this move will help eliminate the unpleasant odour and smoke, thus creating a more pleasant atmosphere throughout the gaming rooms, restaurants, and other recreational areas.
  • The changes may attract a new audience interested in entertainment but previously avoided visiting casinos because of the smoking environment. This can lead not only to an increase in the number of guests but also, as a result, to increased profits for the establishment.

At the same time, avid smokers, which are still quite a lot, will be less likely to visit land-based casinos, where they are forbidden to relax in the usual way. Especially since today, they do not have to visit these establishments to satisfy their gambling needs.

Analyzing the search engine allows you to quickly find many popular operators, including 1win, with the largest number of gambling entertainment. And you can access these games without having to leave home. To register on 1win, it is enough to fill in a few fields in the appropriate window and develop a password. It takes less than a minute to do this and deposit money into your account. Moreover, most of the games can be played in a free demo.

Chippewa Tribe aims to create a “smoke-free” space that combines a healthy environment with the opportunity to relax and enjoy gambling. The new approach to business reflects and supports global trends aimed at caring for public health and reducing the negative impact of tobacco smoke on the health of others.

Recall that earlier, scientists told us about the new harm of smoking. According to new data, the negative impact of this bad habit on the immune system persists for several years after a person quits smoking.

Continue Reading

Health

SpecSMART Eye Clinic Takes Affordable, Quality Care to Ikeja, Environs

Published

on

SpecSMART Eye Clinic

By Modupe Gbadeyanka

The dream of residents of Ikeja and its environs enjoying affordable and quality care has now become a reality as a result of the opening of a new branch of SpecSMART Eye Clinic in the Opebi area of the capital of Lagos State.

SpecSMART Eye Clinic, a leading provider of optometry services in Lagos, commenced operations in Nigeria’s commercial capital in 2022.

Since then, it has been offering top-notch eye care to residents of the metropolis, especially those living on the Island. It has built a strong reputation for delivering high-quality primary eye care and optical products.

However, to extend its services to Lagosians living on the Mainland, it has now opened a new branch in Ikeja, reinforcing its commitment to providing accessible, affordable eye care to a wider community.

Business Post gathered that the clinic’s state-of-the-art services are supported by a team of skilled optometrists and opticians, utilizing cutting-edge digital equipment.

The new Ikeja location will offer a wide range of services, including Automated Eye Examinations using advanced digital equipment for precise diagnosis and personalized care.

In addition, clients will enjoy on-the-spot lens glazing for single vision, bifocals, and varifocals, with additional lens coatings, with services to be rendered seven days a week from 9 am to 9 pm on Mondays to Saturdays, and on Sundays and public holidays from 10 am 7 pm.

Also, the clinic has over 950 frames, ranging from affordable home brands to premium designer options, priced from N18,000, and has flexible appointment scheduling with 24-hour online booking via SpecSMART’s website.

The facility has partnerships with leading HMO providers in the country and offers glaucoma management and other essential eye health services.

According to the company, its introductory packages start from N30,000 and include consultation, frame, and single-vision lenses.

“With the opening of our Ikeja branch, we are ready to serve more individuals who need accessible, cost-effective, and reliable eye care.

“Our aim is to create a positive impact in Nigeria’s optometry sector by combining advanced technology with a patient-centred approach,” the Practice Head and Medical Director of SpecSMART, Dr Adaeze Nwoko, stated.

Continue Reading

Health

FG Begins Vaccination Against Mpox in FCT, Six States

Published

on

Monkeypox mpox

By Adedapo Adesanya

The Federal Ministry of Health and Social Welfare through the National Primary Health Care Development Agency (NPHCDA) has commenced the vaccination against Monkeypox, now known as Mpox.

Business Post reports that Bayelsa, Rivers, Cross River, Akwa Ibom, Enugu, Benue, and the Federal Capital Territory, were selected as pilot states for the vaccination.

An average of 631 persons are expected to be vaccinated across the seven states with two doses of the Mpox vaccine. A buffer for 50 persons will be kept at the national in case of an upsurge in other states.

NPHCDA in a statement posted on its verified X account confirmed the exercise, stressing that the vaccination will help to protect communities and safeguarding health of the people.

In a related development, according to the latest update by the Nigeria Centre for Disease Control (NCDC), there are 1,442 suspected cases of Mpox from 36 states and the Federal Capital Territory, while the number of confirmed cases of the infection was 118 from 28 states and the FCT.

“To prevent the spread of Mpox, we strongly advise the public to avoid contact with animals that may carry the virus, including sick or dead animals in affected areas, avoid handling materials that have been in contact with infected animals, limit unnecessary physical contact with individuals who are infected, practice frequent handwashing with soap and water, and ensure that animal food products are thoroughly cooked before eating.

“It’s also important to use protective clothing and gloves when handling sick animals or their tissues. Similarly, health workers are advised to follow standard safety protocols including droplet precautions when treating patients, use protective equipment including masks, gloves, and gowns, during patient care, and be vigilant for symptoms of Mpox, especially fever and rash, among other measures.”

Continue Reading

Trending